Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic

Sotrovimab was authorized for use in relation to the COVID-19 pandemic, in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 . To provide earlier access to the product in the context of the global pandemic, GlaxoSmithKline will distribute sotrovimab with European French and English labelling in Canada.

COVID - Product safety